OncoCyte Corp
NASDAQ:OCX

Watchlist Manager
OncoCyte Corp Logo
OncoCyte Corp
NASDAQ:OCX
Watchlist
Price: 2.72 USD 1.87% Market Closed
Market Cap: 45.8m USD
Have any thoughts about
OncoCyte Corp?
Write Note

Intrinsic Value

OCX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one OCX stock under the Base Case scenario is 3.58 USD. Compared to the current market price of 2.72 USD, OncoCyte Corp is Undervalued by 24%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

OCX Intrinsic Value
3.58 USD
Undervaluation 24%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
OncoCyte Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for OCX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about OCX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
OncoCyte Corp

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about OncoCyte Corp

Provide an overview of the primary business activities
of OncoCyte Corp.

What unique competitive advantages
does OncoCyte Corp hold over its rivals?

What risks and challenges
does OncoCyte Corp face in the near future?

Has there been any significant insider trading activity
in OncoCyte Corp recently?

Summarize the latest earnings call
of OncoCyte Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for OncoCyte Corp.

Provide P/S
for OncoCyte Corp.

Provide P/E
for OncoCyte Corp.

Provide P/OCF
for OncoCyte Corp.

Provide P/FCFE
for OncoCyte Corp.

Provide P/B
for OncoCyte Corp.

Provide EV/S
for OncoCyte Corp.

Provide EV/GP
for OncoCyte Corp.

Provide EV/EBITDA
for OncoCyte Corp.

Provide EV/EBIT
for OncoCyte Corp.

Provide EV/OCF
for OncoCyte Corp.

Provide EV/FCFF
for OncoCyte Corp.

Provide EV/IC
for OncoCyte Corp.

Show me price targets
for OncoCyte Corp made by professional analysts.

What are the Revenue projections
for OncoCyte Corp?

How accurate were the past Revenue estimates
for OncoCyte Corp?

What are the Net Income projections
for OncoCyte Corp?

How accurate were the past Net Income estimates
for OncoCyte Corp?

What are the EPS projections
for OncoCyte Corp?

How accurate were the past EPS estimates
for OncoCyte Corp?

What are the EBIT projections
for OncoCyte Corp?

How accurate were the past EBIT estimates
for OncoCyte Corp?

Compare the revenue forecasts
for OncoCyte Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of OncoCyte Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of OncoCyte Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of OncoCyte Corp compared to its peers.

Compare the P/E ratios
of OncoCyte Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing OncoCyte Corp with its peers.

Analyze the financial leverage
of OncoCyte Corp compared to its main competitors.

Show all profitability ratios
for OncoCyte Corp.

Provide ROE
for OncoCyte Corp.

Provide ROA
for OncoCyte Corp.

Provide ROIC
for OncoCyte Corp.

Provide ROCE
for OncoCyte Corp.

Provide Gross Margin
for OncoCyte Corp.

Provide Operating Margin
for OncoCyte Corp.

Provide Net Margin
for OncoCyte Corp.

Provide FCF Margin
for OncoCyte Corp.

Show all solvency ratios
for OncoCyte Corp.

Provide D/E Ratio
for OncoCyte Corp.

Provide D/A Ratio
for OncoCyte Corp.

Provide Interest Coverage Ratio
for OncoCyte Corp.

Provide Altman Z-Score Ratio
for OncoCyte Corp.

Provide Quick Ratio
for OncoCyte Corp.

Provide Current Ratio
for OncoCyte Corp.

Provide Cash Ratio
for OncoCyte Corp.

What is the historical Revenue growth
over the last 5 years for OncoCyte Corp?

What is the historical Net Income growth
over the last 5 years for OncoCyte Corp?

What is the current Free Cash Flow
of OncoCyte Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for OncoCyte Corp.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
OncoCyte Corp

Current Assets 4.8m
Cash & Short-Term Investments 3.4m
Receivables 209k
Other Current Assets 1.2m
Non-Current Assets 65.4m
PP&E 6.5m
Intangibles 56.5m
Other Non-Current Assets 2.4m
Current Liabilities 9.1m
Accounts Payable 872k
Accrued Liabilities 7.9m
Other Current Liabilities 364k
Non-Current Liabilities 51.4m
Long-Term Debt 653k
Other Non-Current Liabilities 50.8m
Efficiency

Earnings Waterfall
OncoCyte Corp

Revenue
709k USD
Cost of Revenue
-824k USD
Gross Profit
-115k USD
Operating Expenses
-43.5m USD
Operating Income
-43.6m USD
Other Expenses
-17k USD
Net Income
-43.6m USD

Free Cash Flow Analysis
OncoCyte Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

OCX Profitability Score
Profitability Due Diligence

OncoCyte Corp's profitability score is 8/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
8/100
Profitability
Score

OncoCyte Corp's profitability score is 8/100. The higher the profitability score, the more profitable the company is.

OCX Solvency Score
Solvency Due Diligence

OncoCyte Corp's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
39/100
Solvency
Score

OncoCyte Corp's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OCX Price Targets Summary
OncoCyte Corp

Wall Street analysts forecast OCX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OCX is 4.21 USD with a low forecast of 4.04 USD and a high forecast of 4.46 USD.

Lowest
Price Target
4.04 USD
49% Upside
Average
Price Target
4.21 USD
55% Upside
Highest
Price Target
4.46 USD
64% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for OCX?

Click here to dive deeper.

Dividends

OncoCyte Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for OCX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

OCX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

OncoCyte Corp Logo
OncoCyte Corp

Country

United States of America

Industry

Biotechnology

Market Cap

45.8m USD

Dividend Yield

0%

Description

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 110 full-time employees. The company went IPO on 2015-12-30. The firm is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.

Contact

CALIFORNIA
Irvine
15 Cushing
+19494097600.0
oncocyte.com

IPO

2015-12-30

Employees

110

Officers

President, CEO & Director
Mr. Joshua Riggs
Senior Director, Controller & Principal Accounting Officer
Mr. James Liu
Chief Science Officer
Dr. Ekkehard Schutz M.D., Ph.D.
Chief Financial Officer
Ms. Andrea Susan James
Chief Technology Officer
Mr. Yuh-Min Chiang Ph.D.
VP, General Counsel & Secretary
Mr. Peter Hong
Show More
Senior Vice President of Business Operations
Ms. Sandra O'Donald
Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.
Dr. Michael D. West Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one OCX stock?

The intrinsic value of one OCX stock under the Base Case scenario is 3.58 USD.

Is OCX stock undervalued or overvalued?

Compared to the current market price of 2.72 USD, OncoCyte Corp is Undervalued by 24%.

Back to Top